brigatinib
takeda
['ifct,2101,master,protocol', 'brigatinib', 'nsclc', 'lcsm,(-blcsm)', 'sclc']
#asco22 abs 369924 tip ifct-2101 masterprotocol alk trial: phase ii randomized study of safety and efficacy of brigatinib + carboplatin-pemetrexed or brigatinib as first-line treatment in alk+ nsclc come by &amp; say hi on monday #lcsm
Thoracic oncologist and early phase at Hospices Civils de Lyon Cancer Institute @CHUdeLyon
Medical head @URCOT_lyon
Board member @IFCTlung